Literature DB >> 23490134

Differential expression and tumor necrosis factor-mediated regulation of TNFRSF11b/osteoprotegerin production by human melanomas.

Janine L Oliver1, Matthew P Alexander, Allison G Norrod, Irene M Mullins, David W Mullins.   

Abstract

Tumors escape host immune responses, in part, through the release of immunomodulatory factors and decoy receptors into their microenvironment. Several cancers express surface-bound and soluble members of the tumor necrosis factor (TNF) receptor superfamily, including TNFRSF11b/osteoprotegerin (OPG). In its physiologic role, OPG regulates bone remodeling through competition for osteoclast-activating cytokines and protects newly forming bone from T cell-mediated apoptosis. In multiple tumor types, OPG production is associated with an aggressive phenotype and increased metastasis to bone, but no study has examined OPG production in human metastatic melanoma. We demonstrate that a significant proportion of human metastatic melanomas constitutively produces OPG through a mechanism governed by membrane-bound TNF-α signaling through TNF receptor 1 (TNFR1). These observations both define a specific mechanism that regulates melanoma production of OPG and establish a new molecular target for the therapeutic regulation of OPG.
© 2013 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23490134      PMCID: PMC3964368          DOI: 10.1111/pcmr.12091

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  41 in total

1.  The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens.

Authors:  T L Darrow; C L Slingluff; H F Seigler
Journal:  J Immunol       Date:  1989-05-01       Impact factor: 5.422

2.  Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors:  W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

3.  Metastatic pattern of malignant melanoma. A study of 216 autopsy cases.

Authors:  J K Patel; M S Didolkar; J W Pickren; R H Moore
Journal:  Am J Surg       Date:  1978-06       Impact factor: 2.565

4.  CD4 T cells kill melanoma cells by mechanisms that are independent of Fas (CD95).

Authors:  W D Thomas; P Hersey
Journal:  Int J Cancer       Date:  1998-01-30       Impact factor: 7.396

5.  Taxol-mediated changes in fibrosarcoma-induced immune cell function: modulation of antitumor activities.

Authors:  D W Mullins; T M Walker; C J Burger; K D Elgert
Journal:  Cancer Immunol Immunother       Date:  1997-10       Impact factor: 6.968

6.  Treatment of in-transit metastases from cutaneous melanoma by isolation perfusion with tumour necrosis factor-alpha (TNF-alpha), melphalan and interferon-gamma (IFN-gamma). Dose-finding experience at the National Cancer Institute of Milan.

Authors:  M Vaglini; M Santinami; R Manzi; M G Inglese; N Santoro; L Persiani; F Belli
Journal:  Melanoma Res       Date:  1994-03       Impact factor: 3.599

7.  Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma.

Authors:  Yoichi Mizutani; Hiroki Matsubara; Kosuke Yamamoto; Yong Nan Li; Kazuya Mikami; Koji Okihara; Akihiro Kawauchi; Benjamin Bonavida; Tsuneharu Miki
Journal:  Cancer       Date:  2004-10-15       Impact factor: 6.860

8.  Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2.

Authors:  A Lin; A Minden; H Martinetto; F X Claret; C Lange-Carter; F Mercurio; G L Johnson; M Karin
Journal:  Science       Date:  1995-04-14       Impact factor: 47.728

9.  Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms.

Authors:  B Dérijard; J Raingeaud; T Barrett; I H Wu; J Han; R J Ulevitch; R J Davis
Journal:  Science       Date:  1995-02-03       Impact factor: 47.728

10.  Expression of type A and B tumor necrosis factor (TNF) receptors on melanoma cells can be regulated by dbc-AMP and IFN gamma.

Authors:  S Carrel; F Hartmann; S Salvi; H Albrecht; M Schreyer; D Rimoldi
Journal:  Int J Cancer       Date:  1995-07-04       Impact factor: 7.396

View more
  7 in total

1.  Regulatory effects of bone morphogenetic protein-4 on tumour necrosis factor-α-suppressed Runx2 and osteoprotegerin expression in cementoblasts.

Authors:  Yunlong Wang; Hong He; Zhengguo Cao; Yi Fang; Mingyuan Du; Zhijian Liu
Journal:  Cell Prolif       Date:  2017-02-28       Impact factor: 6.831

2.  NFATc2 is an intrinsic regulator of melanoma dedifferentiation.

Authors:  V Perotti; P Baldassari; A Molla; C Vegetti; I Bersani; A Maurichi; M Santinami; A Anichini; R Mortarini
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

3.  Repurposing L-Menthol for Systems Medicine and Cancer Therapeutics? L-Menthol Induces Apoptosis through Caspase 10 and by Suppressing HSP90.

Authors:  Uzma Faridi; Sunita S Dhawan; Shaifali Pal; Sanchita Gupta; Ashutosh K Shukla; Mahendra P Darokar; Ashok Sharma; Ajit K Shasany
Journal:  OMICS       Date:  2016-01

4.  TNFRSF11B Suppresses Memory CD4+ T Cell Infiltration in the Colon Cancer Microenvironment: A Multiomics Integrative Analysis.

Authors:  Jun-Rong Zhang; Ping Hou; Xiao-Jie Wang; Zong-Qi Weng; Xin-Chang Shang-Guan; Hui Wang; Fang You; Bing-Qiang Lin; Zheng-Yuan Huang; Xian-Qiang Chen
Journal:  Front Immunol       Date:  2021-12-06       Impact factor: 7.561

5.  Ets-2 Propagates IL-6 Trans-Signaling Mediated Osteoclast-Like Changes in Human Rheumatoid Arthritis Synovial Fibroblast.

Authors:  Anil K Singh; Mahamudul Haque; Bhanupriya Madarampalli; Yuanyuan Shi; Benjamin J Wildman; Abdul Basit; Sadik A Khuder; Bhagwat Prasad; Quamarul Hassan; Madhu M Ouseph; Salahuddin Ahmed
Journal:  Front Immunol       Date:  2021-11-02       Impact factor: 7.561

Review 6.  Osteoprotegerin rich tumor microenvironment: implications in breast cancer.

Authors:  Sudeshna Goswami; Neelam Sharma-Walia
Journal:  Oncotarget       Date:  2016-07-05

7.  Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development.

Authors:  Carlos R Figueiredo; Helen Kalirai; Joseph J Sacco; Ricardo A Azevedo; Andrew Duckworth; Joseph R Slupsky; Judy M Coulson; Sarah E Coupland
Journal:  J Pathol       Date:  2020-04       Impact factor: 7.996

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.